Biejia-Ruangan Compound
Chronic Hepatitis B Virus Infection
Explore 11 assets in Chronic Hepatitis B Virus Infection →Floatz Rating
D30/100
Confidence
Indicative
Sponsor
Nanfang Hospital, Southern Medical University
Modality
UNKNOWN
Development Phase
N/A
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
15Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07481032CT.gov Effect of Fufang Biejiaruangan Combined With Antiviral Therapy on the Incidence of Hepatocellular Carcinoma in Patients With Hepatitis B-related Cirrhosis: A Multicenter, Randomized, Placebo-controlled Study | — | Not Yet Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Chronic Hepatitis B Virus Infection
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Biejia-Ruangan Compound (this asset) | Nanfang Hospital, Southern Medical University | N/A | D · 30 |
| Lamivudine | Yonsei University | P4 | BBB |
| Entecavir | Beijing Continent Pharmaceutical Co, Ltd. | P4 | BBB |
| Telbivudine | The Fifth People's Hospital of Suzhou | P4 | BBB |
| Tenofovir Alafenamide | Ningbo No.2 Hospital | P4 | BB |
| Pegyinterferon-Alfa-2A | Huashan Hospital | P4 | BB |
| Adefovir Dipivoxil | Asian-Pacific Alliance of Liver Disease, Beijing | P4 | BB |
| Tenofovir Disoproxil Fumarate | Ningbo No.2 Hospital | P4 | BB |
| Hydronidone | Beijing Continent Pharmaceutical Co, Ltd. | P3 | BB |
+17 more in the Chronic Hepatitis B Virus Infection cohort
Other indications for Biejia-Ruangan Compound
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hepatocellular Carcinoma | — | P4 | B · 59 |
| Cirrhosis Of Liver | — | N/A | D · 30 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Biejia-Ruangan Compound in Chronic Hepatitis B Virus Infection. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/biejia-ruangan-compound-chronic-hepatitis-b-virus-infection
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →